Statins beneficial for heart failure with preserved ejection fraction but not heart failure with reduced ejection fraction?

Circulation Journal

Volumn 79, Issue 3, 2015, Pages 508-509

  Ohte, Nobuyuki ^a   Little, William C ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADRENERGIC SYSTEM; CARDIAC RESYNCHRONIZATION THERAPY; EDITORIAL; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; FEMALE; HEART FAILURE; HEART STROKE VOLUME; MALE;

FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; STROKE VOLUME;

EID: 84923471042     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0016     Document Type: Editorial

References (13)

1. Iwano H, Little WC. Heart failure: What does ejection fraction have to do with it? J Cardiol 2013; 62: 1–3.
2. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: Insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation 2009; 119: 3070–3077.
3. Komajda M, Lam CS. Heart failure with preserved ejection fraction: A clinical dilemma. Eur Heart J 2014; 35: 1022–1032.
4. Borlaug BA. Mechanisms of exercise intolerance in heart failure with preserved ejection fraction. Circ J 2014; 78: 20–32.
5. Goto T, Ohte N, Fukuta H, Wakami K, Tani T, Kimura G. Relationship between effective arterial elastance, total vascular resistance, and augmentation index at the ascending aorta and left ventricular diastolic function in older women. Circ J 2013; 77: 123–129.
6. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263–271.
7. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248–2261.
8. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebocontrolled trial. Lancet 2008; 372: 1231–1239.
9. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: A preliminary report. Circulation 2005; 112: 357–363.
10. Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 2014; 113: 1198–1204.
11. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, et al; On behalf of the CHART-2 Investigators’. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction: A report from the CHART-2 study. Circ J 2015; 79: 574–582.
12. Vyas AK, Guo H, Moss AJ, Olshansky B, McNitt SA, Hall WJ, et al. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47: 769–773.
13. Little WC, Zile MR. HFpEF: Cardiovascular abnormalities not just comorbidities. Circ Heart Fail 2012; 5: 669–671.